Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

Xeris Biopharma Holdings (XERS) Receivables - Net (2020 - 2025)

Xeris Biopharma Holdings' Receivables - Net history spans 6 years, with the latest figure at $51.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Receivables - Net rose 26.31% year-over-year to $51.0 million, compared with a TTM value of $51.0 million through Dec 2025, up 26.31%, and an annual FY2025 reading of $51.0 million, up 26.31% over the prior year.
  • Receivables - Net for Q4 2025 was $51.0 million at Xeris Biopharma Holdings, down from $53.8 million in the prior quarter.
  • The five-year high for Receivables - Net was $53.8 million in Q3 2025, with the low at $13.6 million in Q3 2021.
  • Average Receivables - Net over 5 years is $36.1 million, with a median of $38.3 million recorded in 2023.
  • Year-over-year, Receivables - Net soared 153.91% in 2021 and then fell 10.5% in 2024.
  • Tracing XERS's Receivables - Net over 5 years: stood at $17.5 million in 2021, then skyrocketed by 76.62% to $30.8 million in 2022, then grew by 27.14% to $39.2 million in 2023, then increased by 3.11% to $40.4 million in 2024, then increased by 26.31% to $51.0 million in 2025.
  • Per Business Quant, the three most recent readings for XERS's Receivables - Net are $51.0 million (Q4 2025), $53.8 million (Q3 2025), and $53.0 million (Q2 2025).